DXCM

$84.612.82%2.3199

Dexcom Inc (DXCM)

Date: O: H: L: C: Vol:

전일 마감가:

$82.29

열려 있는:

$83.29

하루 거래량:

2,203,571

상대 거래량:

0.37

시가총액:

$31.56B

수익:

$4.82B

순이익/손실:

$930.40M

주가수익비율:

36.19

EPS:

$2.34

순현금흐름:

$1.43B

1W 성능:

+7.69%

1M 성능:

-0.88%

6M 성능:

+37.91%

1Y 성능:

+45.33%

1일 변동 폭

$82.52$84.70

1주일 범위

$77.69$85.25

52주 변동 폭

$54.11$92.59

Dexcom Inc 주식 (DXCM) 회사 개요

명칭

Dexcom Inc

부문

Healthcare

산업

Medical Devices

전화

(858) 200-0200

주소

6340 SEQUENCE DRIVE, SAN DIEGO, CA, USA

직원

11,100

@dexcom

다음 수익 날짜

null

최신 SEC 제출 서류

SEC

X에서 DXCM에 대한 토론

DXCM vs ABT, MDT, SYK, BSX, EW 비교

주식	시가총액	매출	순이익	현금흐름	주당 순 이익
DXCM Dexcom Inc	$31.55B	$5.10B	$991.00M	$1.43B	$2.34
ABT Abbott Laboratories	$190.14B	$45.13B	$6.28B	$7.38B	$3.09
MDT Medtronic Plc	$126.69B	$37.54B	$5.23B	$5.43B	$3.73
SYK Stryker Corp	$117.23B	$26.30B	$3.62B	$4.57B	$8.63
BSX Boston Scientific Corp	$63.39B	$21.00B	$3.67B	$3.48B	$2.38
EW Edwards Lifesciences Corp	$53.23B	$6.51B	$1.00B	$1.09B	$1.84

Dexcom Inc 주식(DXCM) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2026-10-07	개시	Barclays	Overweight
2026-06-23	개시	Deutsche Bank	Buy
2026-05-12	개시	The Benchmark Company	Buy
2026-03-24	업그레이드	Evercore ISI	In-line → Outperform
2026-01-12	다운그레이드	Barclays	Equal Weight → Underweight
2025-12-02	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2025-11-25	개시	Evercore ISI	In-line
2025-10-21	Resumed	Stifel	Buy
2025-09-08	다운그레이드	Oppenheimer	Outperform → Perform
2025-08-21	개시	Argus	Buy
2025-06-16	개시	Truist	Buy
2025-05-30	개시	Goldman	Buy
2025-04-10	개시	Mizuho	Outperform
2025-02-03	업그레이드	Redburn Atlantic	Neutral → Buy
2025-01-16	업그레이드	Robert W. Baird	Neutral → Outperform
2024-07-26	다운그레이드	JP Morgan	Overweight → Neutral
2024-07-26	다운그레이드	Robert W. Baird	Outperform → Neutral
2024-05-30	개시	Redburn Atlantic	Neutral
2024-03-12	개시	RBC Capital Mkts	Outperform
2023-05-30	Resumed	Morgan Stanley	Equal-Weight
2023-04-17	업그레이드	Raymond James	Outperform → Strong Buy
2023-03-29	개시	UBS	Buy
2023-01-26	개시	Wolfe Research	Outperform
2022-10-18	개시	Barclays	Equal Weight
2022-10-12	개시	Jefferies	Buy
2022-07-15	개시	Bernstein	Outperform
2022-03-02	Resumed	BofA Securities	Buy
2022-02-03	업그레이드	BTIG Research	Neutral → Buy
2022-01-19	업그레이드	Wells Fargo	Equal Weight → Overweight
2022-01-07	업그레이드	Guggenheim	Neutral → Buy
2021-10-18	다운그레이드	Guggenheim	Buy → Neutral
2021-07-21	Resumed	Cowen	Outperform
2021-05-28	업그레이드	Wells Fargo	Underweight → Equal Weight
2021-05-25	개시	Barclays	Overweight
2021-04-15	개시	Atlantic Equities	Overweight
2021-01-06	업그레이드	UBS	Neutral → Buy
2020-10-02	다운그레이드	Wells Fargo	Equal Weight → Underweight
2020-05-27	재확인	Piper Sandler	Overweight
2020-05-14	개시	Wells Fargo	Equal Weight
2020-03-05	개시	Citigroup	Buy
2019-11-07	재확인	Canaccord Genuity	Buy
2019-11-07	업그레이드	Guggenheim	Neutral → Buy
2019-10-23	개시	Stifel	Buy
2018-11-28	개시	UBS	Neutral
2018-10-19	업그레이드	Goldman	Sell → Neutral
2018-09-12	업그레이드	Northland Capital	Under Perform → Market Perform
2018-08-02	재확인	Canaccord Genuity	Buy
2018-07-02	업그레이드	Raymond James	Mkt Perform → Outperform
2018-06-08	업그레이드	JP Morgan	Neutral → Overweight
2018-05-11	개시	BofA/Merrill	Buy
2018-05-03	재확인	Canaccord Genuity	Buy
2018-04-04	개시	Goldman	Sell
2018-04-04	개시	Guggenheim	Neutral
2018-03-23	업그레이드	Robert W. Baird	Neutral → Outperform
2018-01-04	다운그레이드	Northland Capital	Market Perform → Under Perform
2017-09-28	재확인	Wedbush	Outperform

Dexcom Inc (DXCM) 재무 분석

기간	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
기간 종료일	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	4,662.00	4,033.00	3,622.30	2,909.80	2,448.50
Cost of revenue USD (M)	1,860.10	1,594.80	1,333.40	1,026.70	768.00
Gross profit USD (M)	2,801.90	2,438.20	2,288.90	1,883.10	1,680.50
Research and development USD (M)	599.10	552.40	505.80	484.20	517.10
Operating expenses USD (M)	1,890.10	1,838.20	1,691.20	1,491.90	1,414.70
Operating income USD (M)	911.80	600.00	597.70	391.20	265.80
Income before tax USD (M)	1,088.40	709.00	710.40	390.80	173.90
Income tax expense USD (M)	252.10	132.80	168.90	49.60	19.20
Net income USD (M)	836.30	576.20	541.50	341.20	154.70
Basic EPS USD/shares	2.14	1.46	1.40	0.88	1.60
Diluted EPS USD/shares	2.09	1.42	1.30	0.82	1.55
Basic weighted shares shares (M)	390.20	393.60	386.00	389.40	96.70
Diluted weighted shares shares (M)	405.50	412.70	425.50	427.50	100.10
Selling, general and administrative USD (M)	1,291.00	1,285.80	1,185.40	1,000.20	810.50

Dexcom Inc 주식 (DXCM) 내부자 거래

SADIE STERNOct 27 '26
Officer
거래
Proposed Sale
비용
$78.62
#주식
2,565
가치 ($)
201,660
#주식 총계
0
MICHAEL BROWNOct 15 '26
Officer
거래
Proposed Sale
비용
$85.48
#주식
1,700
가치 ($)
145,316
#주식 총계
0
Brown Michael JonOct 15 '26
EVP Chief Legal Compliance Off
거래
Sale
비용
$85.48
#주식
1,700
가치 ($)
145,316
#주식 총계
98,185
Stern SadieSep 28 '26
EVP Chief People & Culture Off
거래
Sale
비용
$86.15
#주식
2,565
가치 ($)
220,975
#주식 총계
123,478
SADIE STERNSep 28 '26
Officer
거래
Proposed Sale
비용
$86.15
#주식
2,565
가치 ($)
220,975
#주식 총계
0
Brown Michael JonSep 15 '26
EVP Chief Legal Compliance Off
거래
Sale
비용
$84.04
#주식
1,700
가치 ($)
142,868
#주식 총계
99,885
AUGUSTINOS NICHOLASSep 15 '26
Director
거래
Sale
비용
$84.04
#주식
6,539
가치 ($)
549,538
#주식 총계
29,293
AUGUSTINOS NICHOLASSep 15 '26
Director
거래
Proposed Sale
비용
$84.04
#주식
6,539
가치 ($)
549,538
#주식 총계
0
MICHAEL BROWNSep 15 '26
Officer
거래
Proposed Sale
비용
$84.04
#주식
1,700
가치 ($)
142,868
#주식 총계
0
AUGUSTINOS NICHOLASSep 14 '26
Director
거래
Proposed Sale
비용
$84.02
#주식
1,550
가치 ($)
130,231
#주식 총계
0

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
SADIE STERN	Officer	Oct 27 '26	Proposed Sale	$78.62	2,565	201,660	0
MICHAEL BROWN	Officer	Oct 15 '26	Proposed Sale	$85.48	1,700	145,316	0
Brown Michael Jon	EVP Chief Legal Compliance Off	Oct 15 '26	Sale	$85.48	1,700	145,316	98,185
Stern Sadie	EVP Chief People & Culture Off	Sep 28 '26	Sale	$86.15	2,565	220,975	123,478
SADIE STERN	Officer	Sep 28 '26	Proposed Sale	$86.15	2,565	220,975	0
Brown Michael Jon	EVP Chief Legal Compliance Off	Sep 15 '26	Sale	$84.04	1,700	142,868	99,885
AUGUSTINOS NICHOLAS	Director	Sep 15 '26	Sale	$84.04	6,539	549,538	29,293
AUGUSTINOS NICHOLAS	Director	Sep 15 '26	Proposed Sale	$84.04	6,539	549,538	0
MICHAEL BROWN	Officer	Sep 15 '26	Proposed Sale	$84.04	1,700	142,868	0
AUGUSTINOS NICHOLAS	Director	Sep 14 '26	Proposed Sale	$84.02	1,550	130,231	0

Dexcom Inc 주식(DXCM)의 최신 뉴스

11:59 AM

Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion - MedTech Dive

11:59 AM

08:00 AM

More than 589 million people worldwide live with diabetes. Nick Jonas shares his story in Dexcom's letter campaign. - Stock Titan

08:00 AM

03:39 AM

DexCom, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:DXCM) 2026-11-02 - Seeking Alpha

03:39 AM

Nov 01, 2026

DexCom: Improving Patient Access Makes It A Long-Term Buy (NASDAQ:DXCM) - Seeking Alpha

Nov 01, 2026

Oct 31, 2026

DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory - Yahoo Finance

Oct 31, 2026

Oct 30, 2026

DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says - Yahoo Finance

Oct 30, 2026

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

Oct 30, 2026

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

Oct 30, 2026

DexCom Inc Reports Q3 2026 Earnings: EPS of $0.72 and Revenue of $1.344 Billion Exceed Estimates - GuruFocus

Oct 29, 2026

DexCom: Q3 Earnings Snapshot - Yahoo Finance

Oct 29, 2026

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance

Oct 29, 2026

Earnings Flash (DXCM) DexCom, Inc. Reports Q3 Revenue $1.34B, vs. FactSet Est of $1.33B - marketscreener.com

Oct 29, 2026

Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67 - marketscreener.com

Oct 29, 2026

Oct 28, 2026

DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus

Oct 28, 2026

Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India

Oct 28, 2026

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November - DexCom, Inc. - Investor Relations

Oct 28, 2026

Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider

Oct 28, 2026

What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga

Oct 27, 2026

Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's

Oct 27, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire

Oct 27, 2026

Oct 26, 2026

Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView

Oct 26, 2026

Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com

Oct 26, 2026

Dexcom Inc Lobbying Profile, 2020 - OpenSecrets

Oct 26, 2026

Form 144 DEXCOM For: 26 October By Investing.com - Investing.com Nigeria

Oct 26, 2026

Oct 24, 2026

DexCom, Inc. (DXCM) Options Chain - Yahoo Finance - Yahoo! Finance Canada

Oct 24, 2026

Oct 23, 2026

DexCom, Inc. Estimates – NASDAQ:DXCM - TradingView

Oct 23, 2026

Oct 21, 2026

Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance

Oct 21, 2026

DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus

Oct 21, 2026

Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily

Oct 21, 2026

DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 21, 2026

DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus

Oct 21, 2026

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill

Oct 21, 2026

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

Oct 21, 2026

Oct 20, 2026

DexCom Inc. Company & People | DXCM.USD - Barron's

Oct 20, 2026

DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's

Oct 20, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

Oct 20, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada

Oct 20, 2026

Oct 19, 2026

Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa

Oct 19, 2026

Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com

Oct 19, 2026

Oct 18, 2026

Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions

Oct 18, 2026

Oct 17, 2026

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha

Oct 17, 2026

Oct 16, 2026

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

Oct 16, 2026

DXCM와(과) 유사한 종목

Dexcom Inc (DXCM)

Dexcom Inc 주식 (DXCM) 회사 개요

DXCM vs ABT, MDT, SYK, BSX, EW 비교

Dexcom Inc 주식(DXCM) 업그레이드 및 다운그레이드

Dexcom Inc (DXCM) 재무 분석

Dexcom Inc 주식 (DXCM) 내부자 거래

Dexcom Inc 주식(DXCM)의 최신 뉴스

Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion - MedTech Dive

More than 589 million people worldwide live with diabetes. Nick Jonas shares his story in Dexcom's letter campaign. - Stock Titan

DexCom, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:DXCM) 2026-11-02 - Seeking Alpha

DexCom: Improving Patient Access Makes It A Long-Term Buy (NASDAQ:DXCM) - Seeking Alpha

DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory - Yahoo Finance

DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says - Yahoo Finance

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Yahoo Finance

DexCom Inc (DXCM) Q3 2026 Earnings Call Highlights: Double-Digit - GuruFocus

What DexCom (DXCM) Said on Its Q3 Earnings Call - TradingView

Why is DexCom stock climbing today? - Investing.com

DexCom Inc Reports Q3 2026 Earnings: EPS of $0.72 and Revenue of $1.344 Billion Exceed Estimates - GuruFocus

DexCom: Q3 Earnings Snapshot - Yahoo Finance

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance

Earnings Flash (DXCM) DexCom, Inc. Reports Q3 Revenue $1.34B, vs. FactSet Est of $1.33B - marketscreener.com

Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67 - marketscreener.com

DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus

Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November - DexCom, Inc. - Investor Relations

Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider

What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance

Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga

Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire

Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView

Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com

Dexcom Inc Lobbying Profile, 2020 - OpenSecrets

Form 144 DEXCOM For: 26 October By Investing.com - Investing.com Nigeria

DexCom, Inc. (DXCM) Options Chain - Yahoo Finance - Yahoo! Finance Canada

DexCom, Inc. Estimates – NASDAQ:DXCM - TradingView

Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance

DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus

Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily

DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

DexCom Inc. Company & People | DXCM.USD - Barron's

DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada

Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa

Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com

Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

DXCM와(과) 유사한 종목